Medical bottles and syringe are seen with Novo Nordisk logo displayed on a screen in the background.
Nurphoto | Nurphoto | Getty Images
Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.
Net profit for the fourth quarter came in at 28.23 billion Danish kroner, versus the 26.09 billion Danish kroner anticipated.
The drug maker posted a 107% year-on-year increase in Wegovy sales to 19.87 billion Danish kroner ($2.76 billion) in the three months to the end of December, slightly missing the 20.02 billion Danish kroner forecast by analysts in a Factset poll late Tuesday.
div { box-sizing: border-box; } .noselect { -webkit-touch-callout: none; /* iOS Safari */ -webkit-user-select: none; /* Safari */ -khtml-user-select: none; /* Konqueror HTML */ -moz-user-select: none; /* Old versions of Firefox */ -ms-user-select: none; /* Internet Explorer/Edge */ user-select: none; /* Non-prefixed version, currently supported by Chrome, Edge, Opera and Firefox */ } .DO-widget-wrapper { width: 100%; max-width: 620px; background-color: #fff; } .DO-logo-row { margin-bottom: 4px; } .DO-body { border-top: 2px #289dcf solid; border-bottom: 2px #289dcf solid; padding: 12px 0 12px 0; margin-bottom: 20px; } .DO-bodycopy .DO-button { font-family: Proxima Nova,Helvetica,Arial,sans-serif; } .DO-bodycopy {color: #424858; font-size: 18px; line-height: 31px; margin-bottom: 12px;} .DO-button { color: #fff; font-size: 16px; font-weight: 600; width: 120px; height: 30px; background-color: #0071bc; border-radius: 6px; text-transform: uppercase; padding: 4px; text-align: center; cursor: pointer; margin-bottom: 4px; text-decoration: none !important; } .DO-button:hover { background-color: #0a94e0; text-decoration: none !important; } @media
This is a breaking news story and will be updated shortly.
